3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Breast Neoplasms
104
Neoplasms
13
Neoplasm Metastasis
8
Sarcoma
6
Pancreatic Neoplasms
6
Ovarian Neoplasms
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Melanoma
5
Leukemia, Myeloid, Acute
5
Colorectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Squamous Cell Carcinoma of Head and Neck
4
Prostatic Neoplasms
4
Lung Neoplasms
4
Liposarcoma
4
Multiple Myeloma
3
Head and Neck Neoplasms
3
Glioblastoma
3
Endometrial Neoplasms
3
Colonic Neoplasms
3
Breast Diseases
3
Brain Neoplasms
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Neoplasm, Residual
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Inflammation
2
Estrogen Receptor-positive Breast Cancer
2
Esophageal Squamous Cell Carcinoma
2
Interventions
Iodine-131
14
trametinib
9
dabrafenib
9
Thyroidectomy
9
Surgical Procedures, Operative
9
lenvatinib
8
Thyroxine
8
Magnetic Resonance Spectroscopy
8
pembrolizumab
7
Paclitaxel
7
anlotinib
6
Thyrotropin Alfa
6
selpercatinib
5
Sorafenib
5
Saline Solution
5
Radiofrequency Ablation
5
Everolimus
5
pazopanib
4
Vemurafenib
4
Sunitinib
4
Radiotherapy
4
Nivolumab
4
Fluorodeoxyglucose F18
4
Dexmedetomidine
4
Cyclophosphamide
4
Biopsy, Fine-Needle
4
Biopsy
4
Bevacizumab
4
apatinib
3
Triiodothyronine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Thyroid Neoplasms
×
palbociclib
×
Clear all
NCT05949424
2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4
Unknown
30 enrolled